-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »SEARCH RESULT
Total Matching Records found : 247
Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »NHRC seeks proper action against HC Registrar General-J Venkatesan
-The Hindu Taking a serious view of the inordinate delay in disbursal of the amount that led to the suicide of the parents of one of the engineers of a ship ‘Pratibha Cauvery,' the National Human Rights Commission has asked the acting Chief Justice of the Madras High Court to take appropriate action against Registrar General G. Chockalingam for his failure to perform his duty. In early March, the National Commission for...
More »Finally, the patients prevail -Sarah Hiddleston
-The Hindu The Supreme Court has denied Novartis a patent for its anti-cancer drug Gleevec. This leaves the door open for Indian pharmaceutical companies to produce their own versions of the drug. Since these are sold at roughly one tenth of the patented brand price, for thousands of cancer patients it means the difference between medicine and no medicine at all. It is not just cancer patients that will benefit, but...
More »A question of standards, not principle-Vinay Sitapati
-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...
More »
